Chronic Myeloid Leukemia (CML) Treatment Global Market Report 2025

Description

Chronic myeloid leukemia (CML) treatment involves addressing the uncontrolled growth of abnormal white blood cells in the blood and bone marrow. These cells, known as myeloid cells, play a crucial role in fighting infections and maintaining the immune system.

The primary types of CML treatment include targeted therapy, chemotherapy, radiation therapy, splenectomy, and stem cell transplant. Targeted therapy is a cancer treatment approach that employs drugs to specifically target genes and proteins supporting the growth and survival of cancer cells. In the context of CML treatment, targeted therapy aims to identify and eliminate specific cancer cell types while minimizing damage to healthy cells. Various drugs, including tyrosine kinase inhibitors, antimetabolites, and others, are utilized in hospitals, clinics, and other healthcare settings for CML treatment. These medications are accessible through hospital pharmacies, retail pharmacies, and online pharmacy platforms.

The chronic myeloid leukemia (CML) treatment market research report is one of a series of new reports from The Business Research Company that provides chronic myeloid leukemia (CML) treatment market statistics, including the chronic myeloid leukemia (CML) treatment industry's global market size, regional shares, competitors with a chronic myeloid leukemia (CML) treatment market share, detailed chronic myeloid leukemia (CML) treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the chronic myeloid leukemia (CML) treatment industry. This chronic myeloid leukemia (CML) treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The chronic myeloid leukemia (CML) treatment market size has grown strongly in recent years. It will grow from $8.23 billion in 2024 to $8.68 billion in 2025 at a compound annual growth rate (CAGR) of 5.4%. The growth in the historic period can be attributed to increased awareness and early detection, clinical trial outcomes, targeted therapies development, patient advocacy and support groups, healthcare infrastructure development

The chronic myeloid leukemia (CML) treatment market size is expected to see strong growth in the next few years. It will grow to $11.39 billion in 2029 at a compound annual growth rate (CAGR) of 7.0%. The growth in the forecast period can be attributed to personalized medicine approaches, combination therapies, increasing patient access to novel therapies, government policies supporting orphan drugs, rising healthcare expenditure. Major trends in the forecast period include global collaboration in research, telemedicine and remote monitoring, development of next-generation tkis, treatment optimization strategies.

The projected rise in the incidence and prevalence of chronic myeloid leukemia (CML) is anticipated to be a significant driver of growth in the chronic myeloid leukemia (CML) treatment market. This type of leukemia, also known as chronic myelogenous leukemia, profoundly impacts the bone marrow and blood by causing an excessive production of immature myeloid cells. Treatment for chronic myeloid leukemia is crucial in slowing down its progression and preventing its advancement to more severe stages. For instance, based on data from the American Society of Clinical Oncology in March 2023, the United States expects a substantial number of individuals, around 35,730, to be diagnosed with multiple myeloma. Furthermore, approximately 12,590 deaths due to this disease are anticipated in 2023. These statistics underscore the pressing need for effective treatments, thereby driving the growth of the chronic myeloid leukemia (CML) treatment market.

The rise of personalized medicine has significantly impacted the chronic myeloid leukemia (CML) treatment market. This approach helps physicians create individualized treatment plans and make informed decisions based on a patient's genetic profile. In CML, personalized medicine focuses on identifying specific molecular targets, notably the BCR-ABL fusion gene, which enhances understanding of the genetic abnormalities that drive the disease in each patient. This facilitates early intervention and tailored preventive strategies. For example, in February 2023, the Personalized Medicine Coalition (PMC), a US-based non-profit organization, reported that personalized medicines designed for specific patient subpopulations with unique biological characteristics accounted for 34 percent of new drug approvals by the U.S. Food and Drug Administration (FDA) in 2022. Consequently, the advancement of personalized medicine is anticipated to propel the growth of the chronic myeloid leukemia (CML) treatment market.

Product innovation is a significant trend gaining traction in the chronic myeloid leukemia (CML) treatment market. Companies in this sector are embracing new technologies to maintain their competitive edge. For example, in August 2022, Novartis AG, a pharmaceutical company based in Switzerland, announced that the European Commission (EC) approved Scemblix for managing adult patients with chronic myeloid leukemia in the chronic phase (Ph+ CML-CP), which is chromosome-positive. Scemblix is the first treatment in Europe that specifically targets the ABL myristoyl pocket, known as a STAMP inhibitor in scientific literature. This innovative mechanism offers a new treatment option for patients who have developed intolerance or resistance to existing tyrosine kinase inhibitors (TKIs). By rethinking the treatment approach, Scemblix meets the needs of those who struggle with current therapies.

Strategic partnerships and collaborations are key focal points for companies aiming to broaden their product spectrum and geographical footprint. For instance, Xspray Pharma, a Sweden-based biotechnology company, forged a partnership with EVERSANA, a US-based life sciences entity, in February 2023. This collaboration aims to support the US launch and commercialization of Dasynoc (XS004), a promising treatment for chronic myeloid leukemia (CML) and acute lymphatic leukemia (ALL). Though pending FDA approval and contingent upon legal conditions, Dasynoc signifies a novel treatment option anticipated to penetrate the lucrative $3.5 billion Tyrosine Kinase Inhibitors market in the United States. Leveraging EVERSANA's specialized commercialization team entrenched in the oncology market, Xspray aims for a tailored and effective approach to introduce Dasynoc, with a projected launch slated for the latter half of 2023. This strategic move holds the promise of significantly enhancing treatment options for CML and ALL patients within the US market.

In August 2022, the US-based multinational pharmaceutical company Bristol Myers Squibb successfully acquired Turning Point Therapeutics for $4.1 billion. This strategic acquisition provides Bristol Myers Squibb with access to Turning Point Therapeutics' pipeline of experimental drugs, notably repotrectinib, designed to target prevalent mutations associated with oncogenesis. Turning Point Therapeutics, based in the US, specializes in the development of precision medicines for cancer and other diseases, including tyrosine kinase inhibitors used in the treatment of chronic myeloid leukemia (CML).

Major companies operating in the chronic myeloid leukemia (CML) treatment market include Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, AstraZeneca plc, Takeda Pharmaceutical Company Limited, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Eisai Co. Ltd., Fresenius Kabi AG, Sun Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Incyte Corporation, Cipla Limited, Dr. Reddy's Laboratories Ltd., Amneal Pharmaceuticals LLC, Lupin Limited, Innovent Biologics Inc., Glenmark Pharmaceuticals Limited, Il-Yang Pharmaceutical Co. Ltd., Accord Healthcare Inc., ARIAD Pharmaceuticals Inc., Orca Bio, Bio-Path Holdings Inc.

North America was the largest region in the chronic myeloid leukemia (CML) treatment market in 2024. The regions covered in the chronic myeloid leukemia (cml) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the chronic myeloid leukemia (cml) treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The chronic myeloid leukemia (CML) treatment market includes revenues earned by entities by providing targeted therapy with tyrosine kinase inhibitors (TKIs). The chronic myeloid leukemia market includes Imatinib, Dasatinib, Nilotinib, Bosutinib, Ponatinib, and Asciminib. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Chronic Myeloid Leukemia (CML) Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on chronic myeloid leukemia (cml) treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for chronic myeloid leukemia (cml) treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The chronic myeloid leukemia (cml) treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Type: Targeted Therapy; Chemotherapy; Radiation Therapy; Splenectomy; Stem Cell Transplant
2) By Drug Type: Tyrosine Kinase Inhibitors; Antimetabolites; Other Drug Types
3) By Application: Hospitals; Clinic; Other Applications
4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
Subsegments:
1) By Targeted Therapy: Tyrosine Kinase Inhibitors (TKIs); Other Targeted Agents
2) By Chemotherapy: Combination Regimens; Single-Agent Therapies
3) By Radiation Therapy: Palliative Radiation; Total Body Irradiation
4) By Splenectomy: Laparoscopic Splenectomy; Open Splenectomy
5) By Stem Cell Transplant: Allogeneic Stem Cell Transplant; Autologous Stem Cell Transplant
Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; AbbVie Inc.; Bayer AG
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r24794

1. Executive Summary

2. Chronic Myeloid Leukemia (CML) Treatment Market Characteristics

3. Chronic Myeloid Leukemia (CML) Treatment Market Trends And Strategies

4. Chronic Myeloid Leukemia (CML) Treatment Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Chronic Myeloid Leukemia (CML) Treatment Growth Analysis And Strategic Analysis Framework

5.1. Global Chronic Myeloid Leukemia (CML) Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Chronic Myeloid Leukemia (CML) Treatment Market Growth Rate Analysis
5.4. Global Chronic Myeloid Leukemia (CML) Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Chronic Myeloid Leukemia (CML) Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Chronic Myeloid Leukemia (CML) Treatment Total Addressable Market (TAM)

6. Chronic Myeloid Leukemia (CML) Treatment Market Segmentation

6.1. Global Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Targeted Therapy
Chemotherapy
Radiation Therapy
Splenectomy
Stem Cell Transplant
6.2. Global Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Tyrosine Kinase Inhibitors
Antimetabolites
Other Drug Types
6.3. Global Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Clinic
Other Applications
6.4. Global Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
6.5. Global Chronic Myeloid Leukemia (CML) Treatment Market, Sub-Segmentation Of Targeted Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Tyrosine Kinase Inhibitors (TKIs)
Other Targeted Agents
6.6. Global Chronic Myeloid Leukemia (CML) Treatment Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Combination Regimens
Single-Agent Therapies
6.7. Global Chronic Myeloid Leukemia (CML) Treatment Market, Sub-Segmentation Of Radiation Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Palliative Radiation
Total Body Irradiation
6.8. Global Chronic Myeloid Leukemia (CML) Treatment Market, Sub-Segmentation Of Splenectomy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Laparoscopic Splenectomy
Open Splenectomy
6.9. Global Chronic Myeloid Leukemia (CML) Treatment Market, Sub-Segmentation Of Stem Cell Transplant, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Allogeneic Stem Cell Transplant
Autologous Stem Cell Transplant

7. Chronic Myeloid Leukemia (CML) Treatment Market Regional And Country Analysis

7.1. Global Chronic Myeloid Leukemia (CML) Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Chronic Myeloid Leukemia (CML) Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Chronic Myeloid Leukemia (CML) Treatment Market

8.1. Asia-Pacific Chronic Myeloid Leukemia (CML) Treatment Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Chronic Myeloid Leukemia (CML) Treatment Market

9.1. China Chronic Myeloid Leukemia (CML) Treatment Market Overview
9.2. China Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Chronic Myeloid Leukemia (CML) Treatment Market

10.1. India Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Chronic Myeloid Leukemia (CML) Treatment Market

11.1. Japan Chronic Myeloid Leukemia (CML) Treatment Market Overview
11.2. Japan Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Chronic Myeloid Leukemia (CML) Treatment Market

12.1. Australia Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Chronic Myeloid Leukemia (CML) Treatment Market

13.1. Indonesia Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Chronic Myeloid Leukemia (CML) Treatment Market

14.1. South Korea Chronic Myeloid Leukemia (CML) Treatment Market Overview
14.2. South Korea Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Chronic Myeloid Leukemia (CML) Treatment Market

15.1. Western Europe Chronic Myeloid Leukemia (CML) Treatment Market Overview
15.2. Western Europe Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Chronic Myeloid Leukemia (CML) Treatment Market

16.1. UK Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Chronic Myeloid Leukemia (CML) Treatment Market

17.1. Germany Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Chronic Myeloid Leukemia (CML) Treatment Market

18.1. France Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Chronic Myeloid Leukemia (CML) Treatment Market

19.1. Italy Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Chronic Myeloid Leukemia (CML) Treatment Market

20.1. Spain Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Chronic Myeloid Leukemia (CML) Treatment Market

21.1. Eastern Europe Chronic Myeloid Leukemia (CML) Treatment Market Overview
21.2. Eastern Europe Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Chronic Myeloid Leukemia (CML) Treatment Market

22.1. Russia Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Chronic Myeloid Leukemia (CML) Treatment Market

23.1. North America Chronic Myeloid Leukemia (CML) Treatment Market Overview
23.2. North America Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Chronic Myeloid Leukemia (CML) Treatment Market

24.1. USA Chronic Myeloid Leukemia (CML) Treatment Market Overview
24.2. USA Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Chronic Myeloid Leukemia (CML) Treatment Market

25.1. Canada Chronic Myeloid Leukemia (CML) Treatment Market Overview
25.2. Canada Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Chronic Myeloid Leukemia (CML) Treatment Market

26.1. South America Chronic Myeloid Leukemia (CML) Treatment Market Overview
26.2. South America Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Chronic Myeloid Leukemia (CML) Treatment Market

27.1. Brazil Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Chronic Myeloid Leukemia (CML) Treatment Market

28.1. Middle East Chronic Myeloid Leukemia (CML) Treatment Market Overview
28.2. Middle East Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Chronic Myeloid Leukemia (CML) Treatment Market

29.1. Africa Chronic Myeloid Leukemia (CML) Treatment Market Overview
29.2. Africa Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Chronic Myeloid Leukemia (CML) Treatment Market Competitive Landscape And Company Profiles

30.1. Chronic Myeloid Leukemia (CML) Treatment Market Competitive Landscape
30.2. Chronic Myeloid Leukemia (CML) Treatment Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Bayer AG Overview, Products and Services, Strategy and Financial Analysis

31. Chronic Myeloid Leukemia (CML) Treatment Market Other Major And Innovative Companies

31.1. Novartis AG
31.2. Bristol-Myers Squibb Company
31.3. AstraZeneca plc
31.4. Takeda Pharmaceutical Company Limited
31.5. Amgen Inc.
31.6. Viatris Inc.
31.7. Teva Pharmaceutical Industries Ltd.
31.8. Eisai Co. Ltd.
31.9. Fresenius Kabi AG
31.10. Sun Pharmaceutical Industries Ltd.
31.11. Otsuka Pharmaceutical Co. Ltd.
31.12. Incyte Corporation
31.13. Cipla Limited
31.14. Dr. Reddy's Laboratories Ltd.
31.15. Amneal Pharmaceuticals LLC

32. Global Chronic Myeloid Leukemia (CML) Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Chronic Myeloid Leukemia (CML) Treatment Market

34. Recent Developments In The Chronic Myeloid Leukemia (CML) Treatment Market

35. Chronic Myeloid Leukemia (CML) Treatment Market High Potential Countries, Segments and Strategies

35.1 Chronic Myeloid Leukemia (CML) Treatment Market In 2029 - Countries Offering Most New Opportunities
35.2 Chronic Myeloid Leukemia (CML) Treatment Market In 2029 - Segments Offering Most New Opportunities
35.3 Chronic Myeloid Leukemia (CML) Treatment Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer